Back to Journals » ClinicoEconomics and Outcomes Research » Volume 10

The number needed to treat and relevant between-trial comparisons of competing interventions

Authors Jansen JP, Khalid JM, Smyth MD, Patel H

Received 19 July 2018

Accepted for publication 9 November 2018

Published 14 December 2018 Volume 2018:10 Pages 865—871

DOI https://doi.org/10.2147/CEOR.S180491

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Professor Giorgio Lorenzo Colombo


Jeroen P Jansen,1 Javaria Mona Khalid,2 Michael D Smyth,3 Haridarshan Patel4

1Evidence Synthesis and Decision Modeling, Precision Xtract, Oakland, CA, USA; 2Evidence and Value Generation, Takeda International – UK Branch, London, UK; 3Global Medical Affairs, Takeda Development Centre Europe Ltd, London, UK; 4Evidence and Value Generation, Takeda International, Deerfield, IL, USA

Abstract: The number needed to treat (NNT) is considered an intuitive as well as popular effect measure. The aims of this review were to 1) explain why we cannot compare trial-specific NNT estimates for the competing treatments evaluated in different randomized controlled trials (RCTs) and 2) outline the principles of how relative treatment effects of different trials can be compared and results can be presented as NNT, without violating the principles of valid between-trial comparisons. Our premise is that ratio measures for relative treatment effects of response outcomes are less prone to effect modification than absolute difference measures of response outcomes. Accordingly, any between-trial comparisons of the efficacy of competing interventions using the study-specific ORs are less likely to be invalid or biased than comparisons based on the study-specific NNT estimates. However, treatment-specific ORs obtained from a meta-analysis or taken directly from an individual study can be transformed into consistent treatment-specific NNT estimates that allow for credible comparisons of treatments when these ratio measures are applied to the same reference response estimate. The theoretical discussion is illustrated with a relevant indirect comparison of biologics for the treatment of ulcerative colitis. Between-trial comparisons directly based on the NNT of individual trials may result in erroneous conclusions and should be avoided. Treatment-specific NNT estimates need to be based on the same probability of response with the common reference treatment against which the interventions are compared.

Keywords: biologics, indirect treatment comparison, network meta-analysis, treatment outcomes, ulcerative colitis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]